- Home
- / BioMarin Pharmaceutical
BioMarin Pharmaceutical
Stock Price
$69.9
2024-10-29
Market Capitalization
$13.3 B
2024-10-29
Revenue
$3.2 B
FY, 2025
BioMarin Pharmaceutical Summary
Company Summary
- Overview
- BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- San Rafael, CA, US | view all locations
- Website
- http://www.biomarin.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jean-Jacques Bienaimé, Chairman and Chief Executive Officer
Elizabeth McKee Anderson, Director
Willard H. Dere, Director
Operating MetricsView all
Phase I/II Trials Products
2
FY, 2016
Phase III Trials Products
2
FY, 2016
Patents Issued
1.2K
FY, 2016
LocationsView all
17 locations detected
San Rafael, CA HQ
United States
770 Lindaro St
Novato, CA
United States
105 Digital Dr
Martínez, Provincia de Buenos Aires
Argentina
Av. Fondo de la Legua 1044 2° piso
Crows Nest, NSW
Australia
119 Willoughby Rd
sao paulo, SP
Brazil
R. James Joule, 92 - o andar - Cidade Monções
Bogotá, Bogotá
Colombia
Ak. 9 #11530
BioMarin Pharmaceutical Financials
Summary Financials
- Revenue (Q1, 2026)
- $766.2M
- Gross profit (Q1, 2026)
- $571.2M
- Net income (Q1, 2026)
- $105.5M
- Cash (Q1, 2026)
- $2.2B
- EBIT (Q1, 2026)
- $129.6M
- Enterprise value
- $12.5B